What Happened?
New York, NY-based BlueRock Therapeutics Appointed Robert Deans as Chief Technology Officer
About the Company
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock`s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
About the Person
Robert Deans is Chief Technology Officer and Head of Research at Rett Syndrome Research Trust. Previously, Robert held various senior IT leadership roles in the industry.
Info Source
News
Short Profile